Skip to main content
Top
Published in: Cardiovascular Drugs and Therapy 3/2024

23-03-2024 | Acute Heart Failure | Invited Editorial

Impairment of Vascular Homeostasis in Acute Heart Failure: Enter the Monocyte?

Authors: Saifei Liu, Indy AJ Lawrie, Bibi Rabia, John D. Horowitz

Published in: Cardiovascular Drugs and Therapy | Issue 3/2024

Login to get access

Excerpt

The major function of the systemic circulation is the delivery of oxygen, nutrients, and circulating hormones such as nitric oxide (NO) to the tissues, together with reciprocal return of tissue metabolites, notably carbon dioxide, to the pulmonary vascular bed for clearance from the body. In 1896, Ernest Starling proposed an equation to summarise the interactions between hydrostatic and tissue oncotic forces which govern exchange of fluid within the peripheral microcirculation [1]. This equation of control of peripheral vascular homeostasis of fluid balance proposed high filtration rates outwards within the arteriolar side of the peripheral circulation, with similar return of fluid on the venular side. This equation has had a longstanding and profound effect on clinical interpretation of circulatory physiology, with the corollary that development of peripheral oedema reflects either increases in venular pressure and/or decreases in oncotic pressure of venous blood. Clinically, the concepts inherent in the original Starling equation are consonant with the gradual development both of peripheral oedema and of pulmonary congestion: for example, plasma albumin concentrations may decrease gradually, or pulmonary venous pressures may rise as a result of impairment of left ventricular relaxation and/or of mitral valve regurgitation. However, in many cases, pulmonary oedema develops suddenly, often in the face of chronic impairment of left ventricular systolic and diastolic function, and not necessarily in association with any acute decline in that function. This common clinical scenario is superficially at odds with the original version of the Starling equation and is most consistent with the occurrences of transient increases in microvascular permeability [2]. …
Literature
2.
go back to reference Becker BF, Chappell D, Jacob M. Endothelial glycocalyx and coronary vascular permeability: the fringe benefit. Basic Res Cardiol. 2010;105(6):687–701.CrossRefPubMed Becker BF, Chappell D, Jacob M. Endothelial glycocalyx and coronary vascular permeability: the fringe benefit. Basic Res Cardiol. 2010;105(6):687–701.CrossRefPubMed
3.
go back to reference Weinbaum S, Cancel LM, Fu BM, Tarbel JM. The glycocalyx and its role in vascular physiology and vascular related diseases. Cardiovasc Eng Technol. 2021;12(1):37–71.CrossRefPubMed Weinbaum S, Cancel LM, Fu BM, Tarbel JM. The glycocalyx and its role in vascular physiology and vascular related diseases. Cardiovasc Eng Technol. 2021;12(1):37–71.CrossRefPubMed
4.
go back to reference Woodcock TE, Woodcock TM. Revised Starling equation and the glycocalyx model of transvascular fluid exchange: an improved paradigm for prescribing intravenous fluid therapy. Br J Anaesth. 2012;108(3):384–94.CrossRefPubMed Woodcock TE, Woodcock TM. Revised Starling equation and the glycocalyx model of transvascular fluid exchange: an improved paradigm for prescribing intravenous fluid therapy. Br J Anaesth. 2012;108(3):384–94.CrossRefPubMed
6.
go back to reference Imam H, Nguyen TH, Stafford I, et al. Impairment of platelet NO signalling in coronary artery spasm: role of hydrogen sulphide. Br J Pharmacol. 2021;178(7):1639–50.CrossRefPubMed Imam H, Nguyen TH, Stafford I, et al. Impairment of platelet NO signalling in coronary artery spasm: role of hydrogen sulphide. Br J Pharmacol. 2021;178(7):1639–50.CrossRefPubMed
7.
go back to reference Yen W, Cai B, Yang J, et al. Endothelial surface glycocalyx can regulate flow-induced nitric oxide production in microvessels in vivo. PLoS One. 2015;10(1):e0117133.CrossRefPubMedPubMedCentral Yen W, Cai B, Yang J, et al. Endothelial surface glycocalyx can regulate flow-induced nitric oxide production in microvessels in vivo. PLoS One. 2015;10(1):e0117133.CrossRefPubMedPubMedCentral
8.
go back to reference Bar A, Targosz-Korecka M, Suraj J, et al. Degradation of glycocalyx and multiple manifestations of endothelial dysfunction coincide in the early phase of endothelial dysfunction before atherosclerotic plaque development in apolipoprotein E/low-density lipoprotein receptor-deficient mice. J Am Heart Assoc. 2019;8(6):e011171.CrossRefPubMedPubMedCentral Bar A, Targosz-Korecka M, Suraj J, et al. Degradation of glycocalyx and multiple manifestations of endothelial dysfunction coincide in the early phase of endothelial dysfunction before atherosclerotic plaque development in apolipoprotein E/low-density lipoprotein receptor-deficient mice. J Am Heart Assoc. 2019;8(6):e011171.CrossRefPubMedPubMedCentral
9.
go back to reference Kei CY, Singh K, Dautov RF, Nguyen TH, Chirkov YY, Horowitz JD. Coronary “microvascular dysfunction”: evolving understanding of pathophysiology, clinical implications, and potential therapeutics. Int J Mol Sci. 2023;24(14):11287.CrossRefPubMedPubMedCentral Kei CY, Singh K, Dautov RF, Nguyen TH, Chirkov YY, Horowitz JD. Coronary “microvascular dysfunction”: evolving understanding of pathophysiology, clinical implications, and potential therapeutics. Int J Mol Sci. 2023;24(14):11287.CrossRefPubMedPubMedCentral
10.
go back to reference Grushko OG, Cho S, Tate AM, et al. Glycocalyx disruption triggers human monocyte activation in acute heart failure syndromes. Cardiovasc Drugs Ther. 2022:1–9. (online ahead of print). Grushko OG, Cho S, Tate AM, et al. Glycocalyx disruption triggers human monocyte activation in acute heart failure syndromes. Cardiovasc Drugs Ther. 2022:1–9. (online ahead of print).
11.
go back to reference Ajaero CN, Procter NE, Chirkov YY, et al. Endothelial dysfunction and glycocalyx shedding in heart failure: insights from patients receiving cardiac resynchronisation therapy. Heart Vessels. 2020;35(2):197–206.CrossRefPubMed Ajaero CN, Procter NE, Chirkov YY, et al. Endothelial dysfunction and glycocalyx shedding in heart failure: insights from patients receiving cardiac resynchronisation therapy. Heart Vessels. 2020;35(2):197–206.CrossRefPubMed
12.
go back to reference Pasupathy S, Tavella R, Grover S, et al. Early use of N-acetylcysteine with nitrate therapy in patients undergoing primary percutaneous coronary intervention for ST-segment-elevation myocardial infarction reduces myocardial infarct size (the NACIAM trial [N-acetylcysteine in acute myocardial infarction]). Circulation. 2017;136(10):894–903.CrossRefPubMed Pasupathy S, Tavella R, Grover S, et al. Early use of N-acetylcysteine with nitrate therapy in patients undergoing primary percutaneous coronary intervention for ST-segment-elevation myocardial infarction reduces myocardial infarct size (the NACIAM trial [N-acetylcysteine in acute myocardial infarction]). Circulation. 2017;136(10):894–903.CrossRefPubMed
13.
go back to reference Nguyen TH, Liu S, Ong GJ, Stafford I, Frenneaux M, Horowitz JD. Glycocalyx shedding is markedly increased during the acute phase of Takotsubo cardiomyopathy. Int J Cardiol. 2017;243:296–9.CrossRefPubMed Nguyen TH, Liu S, Ong GJ, Stafford I, Frenneaux M, Horowitz JD. Glycocalyx shedding is markedly increased during the acute phase of Takotsubo cardiomyopathy. Int J Cardiol. 2017;243:296–9.CrossRefPubMed
14.
go back to reference Cotter G, Metzkor E, Faigenberg Z, et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet. 1998;351(9100):389–93.CrossRefPubMed Cotter G, Metzkor E, Faigenberg Z, et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet. 1998;351(9100):389–93.CrossRefPubMed
15.
go back to reference Beltrame JF, Zeitz CJ, Unger SA, et al. Nitrate therapy is an alternative to furosemide/morphine therapy in the management of acute cardiogenic pulmonary edema. J Card Fail. 1998;4(4):271–9.CrossRefPubMed Beltrame JF, Zeitz CJ, Unger SA, et al. Nitrate therapy is an alternative to furosemide/morphine therapy in the management of acute cardiogenic pulmonary edema. J Card Fail. 1998;4(4):271–9.CrossRefPubMed
Metadata
Title
Impairment of Vascular Homeostasis in Acute Heart Failure: Enter the Monocyte?
Authors
Saifei Liu
Indy AJ Lawrie
Bibi Rabia
John D. Horowitz
Publication date
23-03-2024
Publisher
Springer US
Published in
Cardiovascular Drugs and Therapy / Issue 3/2024
Print ISSN: 0920-3206
Electronic ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-024-07560-6

Other articles of this Issue 3/2024

Cardiovascular Drugs and Therapy 3/2024 Go to the issue